vs
阿斯利康（AZN）与MAINZ BIOMED N.V.（MYNZ）财务数据对比。点击上方公司名可切换其他公司
阿斯利康的季度营收约是MAINZ BIOMED N.V.的67316.7倍（$14.5B vs $214.8K）
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
美因茨生物医学是一家分子诊断企业，专注于开发和商业化胃肠道癌症尤其是结直肠癌的无创早筛检测产品，旗下旗舰产品ColoAlert已在欧洲多国上市，目前正推进北美等全球市场的业务布局。
AZN vs MYNZ — 直观对比
营收规模更大
AZN
是对方的67316.7倍
$214.8K
损益表 — Q2 FY2025 vs Q4 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $14.5B | $214.8K |
| 净利润 | $2.4B | — |
| 毛利率 | 82.9% | 62.7% |
| 营业利润率 | 24.3% | — |
| 净利率 | 16.9% | — |
| 营收同比 | 11.7% | — |
| 净利润同比 | 27.0% | — |
| 每股收益（稀释后） | $1.57 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZNMYNZ
| Q2 25 | $14.5B | — | ||
| Q2 24 | $12.9B | — | ||
| Q4 23 | — | $214.8K | ||
| Q3 23 | — | $181.7K | ||
| Q2 23 | $11.4B | $248.9K | ||
| Q1 23 | — | $1 | ||
| Q3 22 | — | $96.8K | ||
| Q2 22 | $10.8B | $139.2K |
净利润AZNMYNZ
| Q2 25 | $2.4B | — | ||
| Q2 24 | $1.9B | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-6.3M | ||
| Q2 23 | $1.8B | $-8.3M | ||
| Q1 23 | — | $-6.6M | ||
| Q3 22 | — | $-5.6M | ||
| Q2 22 | $360.0M | $-6.9M |
毛利率AZNMYNZ
| Q2 25 | 82.9% | — | ||
| Q2 24 | 83.1% | — | ||
| Q4 23 | — | 62.7% | ||
| Q3 23 | — | 48.0% | ||
| Q2 23 | 82.8% | 59.8% | ||
| Q1 23 | — | — | ||
| Q3 22 | — | 19.2% | ||
| Q2 22 | 72.2% | 58.0% |
营业利润率AZNMYNZ
| Q2 25 | 24.3% | — | ||
| Q2 24 | 21.2% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -3104.9% | ||
| Q2 23 | 21.5% | -3183.9% | ||
| Q1 23 | — | -648755600.0% | ||
| Q3 22 | — | -5657.1% | ||
| Q2 22 | 5.0% | -4989.9% |
净利率AZNMYNZ
| Q2 25 | 16.9% | — | ||
| Q2 24 | 14.9% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -3467.7% | ||
| Q2 23 | 15.9% | -3314.7% | ||
| Q1 23 | — | -656091600.0% | ||
| Q3 22 | — | -5781.8% | ||
| Q2 22 | 3.3% | -4983.3% |
每股收益（稀释后）AZNMYNZ
| Q2 25 | $1.57 | — | ||
| Q2 24 | $1.24 | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-0.39 | ||
| Q2 23 | $1.17 | $-0.56 | ||
| Q1 23 | — | $-0.45 | ||
| Q3 22 | — | $-0.39 | ||
| Q2 22 | $0.23 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1B | $7.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $44.8B | $3.4M |
| 总资产 | $112.4B | $15.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AZNMYNZ
| Q2 25 | $7.1B | — | ||
| Q2 24 | $6.9B | — | ||
| Q4 23 | — | $7.1M | ||
| Q3 23 | — | $9.3M | ||
| Q2 23 | $5.7B | $10.9M | ||
| Q1 23 | — | $10.9M | ||
| Q3 22 | — | $22.0M | ||
| Q2 22 | $4.8B | $26.0M |
股东权益AZNMYNZ
| Q2 25 | $44.8B | — | ||
| Q2 24 | $39.6B | — | ||
| Q4 23 | — | $3.4M | ||
| Q3 23 | — | $3.4M | ||
| Q2 23 | $37.4B | $5.2M | ||
| Q1 23 | — | $9.7M | ||
| Q3 22 | — | $20.8M | ||
| Q2 22 | $36.0B | $23.8M |
总资产AZNMYNZ
| Q2 25 | $112.4B | — | ||
| Q2 24 | $104.3B | — | ||
| Q4 23 | — | $15.4M | ||
| Q3 23 | — | $17.9M | ||
| Q2 23 | $96.5B | $19.3M | ||
| Q1 23 | — | $19.5M | ||
| Q3 22 | — | — | ||
| Q2 22 | $96.6B | $27.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-21.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AZNMYNZ
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $-21.9M | ||
| Q3 23 | — | $-6.5M | ||
| Q2 23 | — | $-5.1M | ||
| Q1 23 | — | $-5.7M | ||
| Q3 22 | — | $-3.6M | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
